DK0800536T3 - Rekombinante IL-5 antagonister, der er nyttige til behandling af IL-5-medierede lidelser - Google Patents

Rekombinante IL-5 antagonister, der er nyttige til behandling af IL-5-medierede lidelser

Info

Publication number: DK0800536T3
Authority: DK; Denmark
Prior art keywords: treatment; pct; recombinant; mediated disorders; antagonists useful
Prior art date: 1994-12-23

Application number

DK95944692T

Other languages

Danish (da)

English (en)

Inventor

Irwin M Chaiken

Mitchell Stuart Gross

Stephen Dudley Holmes

Robert S Ames

Edward Robert Appelbaum

Richard M Cook

Lynette Jane Mcmillan

Timothy Wayne Theisen

Original Assignee

Smithkline Beecham Corp

Smithkline Beecham Plc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-12-23

Filing date

1995-12-22

Publication date

2007-04-02

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27408594&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0800536(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1995-06-06 Priority claimed from US08/470,110 external-priority patent/US5693323A/en

1995-12-22 Application filed by Smithkline Beecham Corp, Smithkline Beecham Plc filed Critical Smithkline Beecham Corp

2007-04-02 Application granted granted Critical

2007-04-02 Publication of DK0800536T3 publication Critical patent/DK0800536T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5409—IL-5
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Immunology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Bioinformatics & Cheminformatics (AREA)
Biochemistry (AREA)
Cell Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Pulmonology (AREA)
Zoology (AREA)
Hematology (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Pathology (AREA)
General Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Physics & Mathematics (AREA)
Food Science & Technology (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Tropical Medicine & Parasitology (AREA)
Otolaryngology (AREA)
Heart & Thoracic Surgery (AREA)
Dermatology (AREA)

DK95944692T 1994-12-23 1995-12-22 Rekombinante IL-5 antagonister, der er nyttige til behandling af IL-5-medierede lidelser DK0800536T3 (da)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US36313194A	1994-12-23	1994-12-23
US08/470,110 US5693323A (en)	1994-12-23	1995-06-06	Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US08/467,420 US5683892A (en)	1994-12-23	1995-06-06	DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
PCT/US1995/017082 WO1996021000A2 (en)	1994-12-23	1995-12-22	Recombinant il-5 antagonists useful in treatment of il-5 mediated disorders

Publications (1)

Publication Number	Publication Date
DK0800536T3 true DK0800536T3 (da)	2007-04-02

Family

ID=27408594

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK95944692T DK0800536T3 (da)	1994-12-23	1995-12-22	Rekombinante IL-5 antagonister, der er nyttige til behandling af IL-5-medierede lidelser

Country Status (22)

Country	Link
US (1)	US6129913A (pt)
EP (1)	EP0800536B1 (pt)
JP (2)	JP2001523083A (pt)
CN (1)	CN100391977C (pt)
AT (1)	ATE346867T1 (pt)
AU (1)	AU708951B2 (pt)
BR (1)	BR9510499B1 (pt)
CA (1)	CA2208503C (pt)
CZ (1)	CZ297045B6 (pt)
DE (1)	DE69535319T2 (pt)
DK (1)	DK0800536T3 (pt)
ES (1)	ES2277336T3 (pt)
FI (1)	FI119374B (pt)
HK (1)	HK1003651A1 (pt)
HU (1)	HU222992B1 (pt)
LU (1)	LU92912I2 (pt)
MX (1)	MX9704779A (pt)
NL (1)	NL300787I1 (pt)
NO (2)	NO324181B1 (pt)
NZ (1)	NZ301916A (pt)
PL (1)	PL194312B1 (pt)
WO (1)	WO1996021000A2 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5683892A (en) *	1994-12-23	1997-11-04	Smithkline Beecham Corporation	DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US5783184A (en) *	1994-12-23	1998-07-21	Smithkline Beecham Corporation	Method for treatment and diagnosis of IL-5 mediated disorders
EP1914244B1 (en) *	1999-04-09	2013-05-29	Kyowa Hakko Kirin Co., Ltd.	Method of modulating the activity of functional immune molecules
US6946292B2 (en)	2000-10-06	2005-09-20	Kyowa Hakko Kogyo Co., Ltd.	Cells producing antibody compositions with increased antibody dependent cytotoxic activity
ATE435239T1 (de) *	2002-03-29	2009-07-15	Schering Corp	Menschliche monoklonale antikörper gegen interleukin-5 sowie diese umfassende verfahren und zusammensetzungen
CA2481920A1 (en)	2002-04-09	2003-10-16	Kyowa Hakko Kogyo Co., Ltd.	Antibody composition-containing medicament
US20070219117A1 (en) *	2003-10-27	2007-09-20	Medvet Science Pty Ltd	Bidentate motif and methods of use
JP4954709B2 (ja) *	2004-10-28	2012-06-20	協和発酵キリン株式会社	子宮内膜症治療剤
JP2010526088A (ja)	2007-04-30	2010-07-29	グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー	抗ｉｌ−５抗体を投与するための方法
JP4335286B2 (ja)	2008-02-08	2009-09-30	ファナック株式会社	部品保護機能を備えたロボット制御装置及びロボット制御方法
CN102026660A (zh)	2008-03-28	2011-04-20	葛兰素史密斯克莱有限责任公司	治疗方法
UY33202A (es) *	2010-01-28	2011-08-31	Glaxo Group Ltd	Proteínas de unión a cd127
EA201390923A1 (ru)	2010-12-22	2013-12-30	Сефалон Острэйлиа Пти Лтд.	Модифицированное антитело с улучшенным полупериодом существования
TWI750133B (zh)	2015-08-24	2021-12-21	美商葛蘭素史密斯克萊有限責任公司	生藥組成物
EP3436480A4 (en) *	2016-03-30	2019-11-27	Musc Foundation for Research Development	METHOD FOR THE TREATMENT AND DIAGNOSIS OF CANCER BY TARGETING GLYCOPROTEIN A REPETITION PREDOMINANT (GARP) AND FOR EFFECTIVE IMMUNOTHERAPY ALONE OR IN COMBINATION
AR110564A1 (es) *	2016-12-23	2019-04-10	Cephalon Inc	Anticuerpos anti-il-5
JP7224304B2 (ja)	2017-05-26	2023-02-17	グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド	生物医薬組成物および関連の方法
CN111065651B (zh) *	2017-09-29	2023-07-14	江苏恒瑞医药股份有限公司	Il-5抗体、其抗原结合片段及医药用途
CN109942706A (zh) *	2017-12-21	2019-06-28	三生国健药业（上海）股份有限公司	结合人il-5的单克隆抗体、其制备方法和用途
CN113366016B (zh) *	2018-12-12	2022-12-16	上海开拓者生物医药有限公司	抗人白细胞介素5(il-5)单克隆抗体及其应用
BR112021019272A2 (pt) *	2019-03-29	2022-01-04	Jiangsu Hengrui Medicine Co	Composição farmacêutica contendo anticorpo contra il-5 e uso da mesma

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8800397D0 (en) *	1988-01-08	1988-02-10	Sandoz Ltd	Improvements in/relating to organic compounds
US5096704A (en) *	1988-11-03	1992-03-17	Schering Corporation	Method of treating eosinophilia
IL92180A (en) *	1988-11-03	1997-04-15	Schering Corp	Pharmaceutical composition for preventing or reducing eosinophilia
US5530101A (en) *	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
ZA929328B (en) *	1991-12-02	1993-07-20	Fluor Corp	Apparatus and method for economic use of excess compressed air when firing low caloric-value gas in a combustion gas turbine.
HUT67943A (en) *	1992-02-06	1995-05-29	Schering Corp	Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5
JPH06141885A (ja) *	1992-11-05	1994-05-24	Chemo Sero Therapeut Res Inst	モノクローナル抗体
WO1995014040A1 (en) *	1993-11-19	1995-05-26	Baylor College Of Medicine	Monoclonal antibodies specific for human interleukin-5
GB9412230D0 (en) *	1994-06-17	1994-08-10	Celltech Ltd	Interleukin-5 specific recombiant antibodies
US5783184A (en) *	1994-12-23	1998-07-21	Smithkline Beecham Corporation	Method for treatment and diagnosis of IL-5 mediated disorders
US5683892A (en) *	1994-12-23	1997-11-04	Smithkline Beecham Corporation	DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
WO2001012646A1 (en) *	1999-08-19	2001-02-22	Smithkline Beecham Corporation	Sialoadhesin factor-1 agonist and antagonist antibodies

1995
- 1995-12-22 AT AT95944692T patent/ATE346867T1/de active
- 1995-12-22 BR BRPI9510499-2A patent/BR9510499B1/pt active IP Right Grant
- 1995-12-22 ES ES95944692T patent/ES2277336T3/es not_active Expired - Lifetime
- 1995-12-22 JP JP52118996A patent/JP2001523083A/ja not_active Withdrawn
- 1995-12-22 CN CNB951977016A patent/CN100391977C/zh not_active Expired - Lifetime
- 1995-12-22 MX MX9704779A patent/MX9704779A/es unknown
- 1995-12-22 WO PCT/US1995/017082 patent/WO1996021000A2/en active IP Right Grant
- 1995-12-22 CZ CZ0196397A patent/CZ297045B6/cs not_active IP Right Cessation
- 1995-12-22 NZ NZ301916A patent/NZ301916A/xx not_active IP Right Cessation
- 1995-12-22 EP EP95944692A patent/EP0800536B1/en not_active Expired - Lifetime
- 1995-12-22 US US08/637,647 patent/US6129913A/en not_active Expired - Lifetime
- 1995-12-22 AU AU47450/96A patent/AU708951B2/en not_active Expired
- 1995-12-22 PL PL95321088A patent/PL194312B1/pl unknown
- 1995-12-22 HU HU9901120A patent/HU222992B1/hu active Protection Beyond IP Right Term
- 1995-12-22 DK DK95944692T patent/DK0800536T3/da active
- 1995-12-22 CA CA002208503A patent/CA2208503C/en not_active Expired - Lifetime
- 1995-12-22 DE DE69535319T patent/DE69535319T2/de not_active Expired - Lifetime
1997
- 1997-06-20 NO NO19972913A patent/NO324181B1/no not_active IP Right Cessation
- 1997-06-23 FI FI972703A patent/FI119374B/fi not_active IP Right Cessation
1998
- 1998-04-09 HK HK98103015A patent/HK1003651A1/xx not_active IP Right Cessation
2007
- 2007-10-16 JP JP2007269236A patent/JP2008029355A/ja not_active Withdrawn
2015
- 2015-12-16 LU LU92912C patent/LU92912I2/xx unknown
- 2015-12-18 NO NO2015027C patent/NO2015027I2/no unknown
- 2015-12-18 NL NL300787C patent/NL300787I1/nl unknown

Also Published As

Publication number	Publication date
NL300787I2 (pt)	2016-04-05
FI972703A0 (fi)	1997-06-23
AU708951B2 (en)	1999-08-19
CZ297045B6 (cs)	2006-08-16
WO1996021000A2 (en)	1996-07-11
EP0800536B1 (en)	2006-11-29
EP0800536A2 (en)	1997-10-15
NO2015027I1 (no)	2015-12-18
PL321088A1 (en)	1997-11-24
CA2208503C (en)	2009-12-01
FI972703L (fi)	1997-08-22
ATE346867T1 (de)	2006-12-15
PL194312B1 (pl)	2007-05-31
JP2008029355A (ja)	2008-02-14
HK1003651A1 (en)	1998-11-06
AU4745096A (en)	1996-07-24
US6129913A (en)	2000-10-10
EP0800536A4 (en)	2004-12-01
CA2208503A1 (en)	1996-07-11
FI119374B (fi)	2008-10-31
HU222992B1 (hu)	2004-01-28
NL300787I1 (pt)	2016-04-05
NO324181B1 (no)	2007-09-03
NO2015027I2 (no)	2016-01-04
CN100391977C (zh)	2008-06-04
ES2277336T3 (es)	2007-07-01
DE69535319D1 (de)	2007-01-11
CN1175263A (zh)	1998-03-04
WO1996021000A3 (en)	1996-09-06
BR9510499B1 (pt)	2009-05-05
MX9704779A (es)	1997-09-30
NO972913D0 (no)	1997-06-20
NZ301916A (en)	1999-05-28
HUT78055A (hu)	1999-07-28
BR9510499A (pt)	1999-03-30
JP2001523083A (ja)	2001-11-20
DE69535319T2 (de)	2007-07-19
LU92912I2 (fr)	2016-02-16
NO972913L (no)	1997-08-19
CZ196397A3 (en)	1997-10-15

Publication	Publication Date	Title
DK0800536T3 (da)	2007-04-02	Rekombinante IL-5 antagonister, der er nyttige til behandling af IL-5-medierede lidelser
BR0008688A (pt)	2002-01-08	Antagonistas de il-18 recombinantes utilizáveis no tratamento de distúrbios mediados por il-18
SE9604793D0 (sv)	1996-12-20	New polymorphs
DK0771197T3 (da)	2003-06-23	Anvendelse af heterocykliske forbindelser som dopamin-D3-ligander
DK0726765T3 (da)	2001-10-15	Apparat og fremgangsmåde til fremstilling af faste former med styret frigivelse af den aktive bestanddel
LU91271I2 (fr)	2006-10-02	Natalizumab et ses dérivés pharmaceutiquement acceptables (TYSABRI)
DE69132141D1 (de)	2000-05-31	Neuroprotective indolone und verwandte derivate
FI971967A0 (fi)	1997-05-07	Dioksomorfoliinien käyttö sisäloisten torjuntaan, uusia dioksomorfiineja ja menetelmä niiden valmistamiseksi
YU7797A (sh)	2000-10-30	Kombinovana terapija za osteoporozu
UA48940C2 (uk)	2002-09-16	Рекомбінатні il4 антитіла, які використовуються для лікування il4-опосередкованих порушень
BR9910180A (pt)	2001-01-09	Composição farmacêutica, processos para o tratamento de uma condição associada com a transmissão reduzida de nicotina, para identificação de um modulador positivo de um agonista receptor nicotìnico e para identificação de um composto, composto, e, uso de um modulador positivo de um agonista receptor nicotìnico
DK0473671T3 (da)	1994-09-19	Anvendelse af sigma-receptorligander til fremstilling af et anxiolytisk middel
DK0712311T3 (da)	1999-06-21	Antiglucocorticoidsteroider til behandling af angstlidelser
ATE226947T1 (de)	2002-11-15	2-substituierte 1,2,5-thiadiazolidin-3-on-1,1- dioxiden, zusammensetzung und deren verwendung
DE69836678D1 (de)	2007-02-01	Chinolin- und chinazolinderivate als antagonisten des corticotropin freisetzenden faktors (crf)
DK0989973T3 (da)	2005-10-17	Chalconer med antiproliferativ aktivitet
FI973221A0 (fi)	1997-08-04	1-aryyli-2-asyyliammo-etaaniyhdisteitä ja niiden käyttö neurokiniiniantagonisteina, erityisesti neurokiniini 1 antagonisteina
ES2088128T3 (es)	1996-08-01	Aminosulfonilureas inhibidoras de acat.
DK0786004T3 (da)	2001-10-22	Kloning, ekspression og karakterisering af en hidtil ukendt form af phosphatidylinositol-3-kinase
DE69526584D1 (de)	2002-06-06	Verwendung von immunosuppressiva zur behandlung der schizophrenie
ES2091039T3 (es)	1996-10-16	Nuevos bis-fenil-hexenos.
SE9404438D0 (sv)	1994-12-21	New process